MedicaidCoverageHigh impact
Skin and Tissue Substitutes - MEDICAID - INDIANA (New)
Humana·IN · Wound Care, Podiatry, General Surgery +3 more·Medicaid
Effective date
May 20, 2026
We identified it
Oct 15, 2026
Summary
Humana Indiana Medicaid has established new coverage criteria for skin and tissue substitutes (cellular and acellular matrices) effective May 20, 2026. Coverage is limited to two indications: partial- and full-thickness diabetic foot ulcers (DFU) and chronic venous leg ulcers (VLU), both >4 weeks duration, when used with standard wound therapy and meeting specific clinical prerequisites. All other indications are not covered. This is a historical material discovery—the policy became effective over 4 months prior to analysis date (2026-10-15).
Action Required
Already effective 2026-05-20: Verify whether the practice has implemented Humana Indiana Medicaid coverage restrictions for skin and tissue substitutes (HCPCS codes A2001–A2035, A4100, C9354, C9358–C9364, Q4101–Q4105) and confirm current applicability. Billing team must ensure that prior authorization or claims submissions for these products now comply with the two covered indications only: (1) diabetic foot ulcers >4 weeks duration meeting all stated clinical criteria (offloading, comprehensive assessment, diabetes diagnosis, repositioning, moist dressings, infection treatment, glycemic control), and (2) chronic venous leg ulcers >4 weeks duration meeting all stated criteria (clinical history, vascular assessment, compression therapy, moist dressings, infection treatment, glycemic control if diabetic). All other indications must be denied as not medically necessary. Review current claim submissions and billing software logic to confirm denials are issued correctly for out-of-scope uses (e.g., breast reconstruction, burn treatment, ocular defects, plantar fasciitis, surgical wounds). Confirm EPSDT medical necessity review is applied for members under age 21. Update internal authorization workflows and claim templates to reflect these limitations.